Drug Trial Radar · NCT07181265
Drug-Drug Interaction of JMKX003142 With Amiodarone and Febuxostat in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Sep 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Oct 30, 2025
Primary completion
Apr 30, 2026
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- JemincareIndustry
- Sponsor type
- Industry
- First posted
- Sep 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a open-label, non-randomized, multiple oral dosings, three-period, drug-drug interaction study of JMKX003142 tablet, Amiodarone Hydrochloride Tablets and Febuxostat Tablets in Chinese healthy adult subjects
Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
Amiodarone Hydrochloride TabletsDrug
Cohort 1: The intervention is for study of drug drug interaction of JMKX003142 when administered with Amiodarone
Febuxostat TabletsDrug
Cohort 2: The intervention is for study of drug drug interaction of JMKX003142 when administered with Febuxostat Tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax,ssTime frame: up to 7 days
- AUC0-tauTime frame: up tp 7 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.